Serum Vitamin and Metabolite Concentrations Before and After 4 Months of Therapy in Patients Randomized to Parenteral Cyanocobalamin
Patient No. . | Therapy* . | Serum Cobalamin (pg/mL)3-151 . | Serum Folate (ng/mL)3-151 . | Serum Methylmalonic Acid (nmol/L)3-151 . | Serum Total Homocysteine (μmol/L)3-151 . | ||||
---|---|---|---|---|---|---|---|---|---|
Pre3-152 . | 4 mo3-152 . | Pre . | 4 mo . | Pre . | 4 mo . | Pre . | 4 mo . | ||
19 | IM | 90 | 170 | 9.0 | 4.9 | 22,200 | 339 | 45.0 | 14.5 |
20 | IM | 35 | 190 | 14.4 | 13.8 | 19,600 | 852 | 100.8 | 8.5 |
21 | IM | 70 | 350 | 2.6 | 2.7 | 2,510 | 238 | 70.9 | 9.1 |
22 | IM | 75 | 635 | 10.0 | 5.7 | 1,760 | 289 | 55.2 | 12.9 |
23 | IM | 45 | 175 | 5.4 | 5.7 | 1,170 | 370 | 23.9 | 10.0 |
24 | IM | 80 | 200 | 4.7 | 6.7 | 1,280 | 170 | 55.2 | 9.3 |
25 | IM | 30 | 230 | 8.3 | 8.5 | 1,070 | 444 | 71.8 | 11.4 |
26 | IM | 95 | 380 | 4.1 | 6.1 | 1,010 | 219 | 38.3 | 12.1 |
27 | IM | 170 | 390 | 3.4 | 3.9 | 665 | 120 | 14.4 | 19.0 |
28 | IM | 160 | 365 | 2.5 | 2.5 | 659 | 166 | 21.6 | 18.1 |
29 | IM | 110 | 295 | 3.4 | 3.7 | 502 | 172 | 26.0 | 17.3 |
30 | IM | 50 | 175 | 4.03-153 | 13.7 | 421 | 177 | 21.3 | 8.4 |
31 | IM | 120 | —3-155 | 5.1 | 6.1 | 418 | 188 | 11.4 | 7.5 |
32 | IM | 155 | 690 | 25.6 | 50.2 | 396 | 136 | 10.4 | 7.5 |
33 | IM | 140 | 300 | 3.4 | 1.8 | 272 | 96 | 34.3 | 17.8 |
Mean ± SD | IM | 95 ± 92 | 325 ± 165 | 7.1 ± 6.1 | 9.1 ± 11.9 | 3,630 ± 7,040 | 265 ± 190 | 40.0 ± 26.2 | 12.2 ± 4.1 |
Patient No. . | Therapy* . | Serum Cobalamin (pg/mL)3-151 . | Serum Folate (ng/mL)3-151 . | Serum Methylmalonic Acid (nmol/L)3-151 . | Serum Total Homocysteine (μmol/L)3-151 . | ||||
---|---|---|---|---|---|---|---|---|---|
Pre3-152 . | 4 mo3-152 . | Pre . | 4 mo . | Pre . | 4 mo . | Pre . | 4 mo . | ||
19 | IM | 90 | 170 | 9.0 | 4.9 | 22,200 | 339 | 45.0 | 14.5 |
20 | IM | 35 | 190 | 14.4 | 13.8 | 19,600 | 852 | 100.8 | 8.5 |
21 | IM | 70 | 350 | 2.6 | 2.7 | 2,510 | 238 | 70.9 | 9.1 |
22 | IM | 75 | 635 | 10.0 | 5.7 | 1,760 | 289 | 55.2 | 12.9 |
23 | IM | 45 | 175 | 5.4 | 5.7 | 1,170 | 370 | 23.9 | 10.0 |
24 | IM | 80 | 200 | 4.7 | 6.7 | 1,280 | 170 | 55.2 | 9.3 |
25 | IM | 30 | 230 | 8.3 | 8.5 | 1,070 | 444 | 71.8 | 11.4 |
26 | IM | 95 | 380 | 4.1 | 6.1 | 1,010 | 219 | 38.3 | 12.1 |
27 | IM | 170 | 390 | 3.4 | 3.9 | 665 | 120 | 14.4 | 19.0 |
28 | IM | 160 | 365 | 2.5 | 2.5 | 659 | 166 | 21.6 | 18.1 |
29 | IM | 110 | 295 | 3.4 | 3.7 | 502 | 172 | 26.0 | 17.3 |
30 | IM | 50 | 175 | 4.03-153 | 13.7 | 421 | 177 | 21.3 | 8.4 |
31 | IM | 120 | —3-155 | 5.1 | 6.1 | 418 | 188 | 11.4 | 7.5 |
32 | IM | 155 | 690 | 25.6 | 50.2 | 396 | 136 | 10.4 | 7.5 |
33 | IM | 140 | 300 | 3.4 | 1.8 | 272 | 96 | 34.3 | 17.8 |
Mean ± SD | IM | 95 ± 92 | 325 ± 165 | 7.1 ± 6.1 | 9.1 ± 11.9 | 3,630 ± 7,040 | 265 ± 190 | 40.0 ± 26.2 | 12.2 ± 4.1 |
*IM indicates intramuscular therapy.
Normal ranges and conversion factors for serum vitamin concentrations as indicated in footnote to Table 2.
Pre and 4 mo as in footnote to Table 3.
After 1 week of oral folic acid at 1 mg/d; previous serum folate level was less than 1.0 ng/mL.
Value excluded from analysis due to error in sampling immediately after parenteral dose.